Muniz Eduardo Correa, Verdi Renato, Leão Joice Aparecida, Back Alberto, Nascimento Vladimir Pinheiro do
a Zoetis Indústria de Produtos Veterinários Ltda , São Paulo , SP , Brazil.
b Mercolab Laboratórios Ltda , Cascavel , PR , Brazil.
Avian Pathol. 2017 Dec;46(6):676-682. doi: 10.1080/03079457.2017.1348598. Epub 2017 Aug 22.
Salmonellosis ranks among the major diseases of commercial poultry, and its presence in poultry flocks is responsible for economic losses and risks related to public health. Vaccines are an important tool within integrated programmes to control salmonellosis. The purpose of this study was to assess cross-protection provided by the Poulvac® ST vaccine in the control of Salmonella Heidelberg in experimentally challenged 3- and 21-day-old birds. Eighty birds were identified and separated into four treatments (T1: vaccinated and challenged at 3 days of age, T2: unvaccinated and challenged at 3 days of age, T3: vaccinated and challenged at 21 days of age, and T4: unvaccinated and challenged at 21 days of age). The inoculum was produced from a Brazilian field strain of SH. At the end of the experiment, caecum and liver/spleen samples were collected for quantitative and qualitative analysis of SH, respectively. Analysis of the liver/spleen showed that Poulvac® ST significantly (P ≤ 0.05) reduced the percentage of SH positivity in the group challenged at 3 days of age, while in the group challenged at 21 days this difference was almost considered significant (P = 0.1818). On the other hand, there was no statistically significant difference in SH count in the caecum (CFU/g) in the group challenged at 3 days, but for the group challenged at 21 days the SH counts were significantly (P ≤ 0.05) lower in the vaccinated group when compared to the positive control.
沙门氏菌病是商业家禽的主要疾病之一，家禽群中存在该病菌会造成经济损失并带来公共卫生风险。疫苗是综合防控沙门氏菌病计划中的一项重要工具。本研究的目的是评估Poulvac® ST疫苗在实验性攻毒的3日龄和21日龄禽类中对控制海德堡沙门氏菌的交叉保护作用。挑选出80只禽类并分为四种处理组（T1：3日龄时接种疫苗并攻毒，T2：3日龄时未接种疫苗并攻毒，T3：21日龄时接种疫苗并攻毒，T4：21日龄时未接种疫苗并攻毒）。接种物由一株巴西海德堡沙门氏菌田间菌株制备。实验结束时，分别采集盲肠和肝脏/脾脏样本用于对海德堡沙门氏菌进行定量和定性分析。对肝脏/脾脏的分析表明，Poulvac® ST显著（P≤0.05）降低了3日龄攻毒组中海德堡沙门氏菌阳性率，而在21日龄攻毒组中，这种差异几乎被认为具有显著性（P = 0.1818）。另一方面，3日龄攻毒组盲肠中的海德堡沙门氏菌计数（CFU/g）没有统计学上的显著差异，但对于21日龄攻毒组，与阳性对照组相比，接种疫苗组的海德堡沙门氏菌计数显著（P≤0.05）更低。
